Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZYESAMI in Critical COVID-19
NCT04311697Phase 3Completed
- Sponsor
- APR Applied Pharma Research
- Start
- May 2020
- Primary completion
- Feb 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aviptadil in coronavirus disease 2019 (COVID-19), respiratory failure, acute respiratory distress syndrome (ARDS), sponsored by APR Applied Pharma Research. Started May 2020; status: completed.
02
Drugs
aviptadil
03
Conditions
coronavirus disease 2019 (COVID-19)respiratory failureacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04311697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04311697.